International Journal of Hematology

DOI: 10.1007/s12185-019-02717-8 Pages: 543-549

Vitamin B6 deficiency is prevalent in primary and secondary myelofibrosis patients

1. Juntendo University School of Medicine, Department of Hematology

2. Juntendo University Urayasu Hospital, Department of Hematology

3. Juntendo University Nerima Hospital, Division of Hematology, Department of Medicine

Correspondence to:
Hajime Yasuda
Tel: +81 3 3813-3111



Vitamin B6 (VB6) deficiency contributes to oncogenesis and tumor progression in certain cancers, and is prevalent in cancer patients in general. VB6 is also an essential element of heme synthesis, and deficiency can lead to anemia. Primary myelofibrosis (PMF) and secondary myelofibrosis (sMF) are myeloproliferative neoplasms often presenting with anemia along with other cytopenias. We performed a prospective study to determine whether PMF and sMF patients suffer from VB6 deficiency, and whether VB6-deficient patients show improvement of anemias with VB6 supplementation. Twelve PMF patients and 11 sMF patients were analyzed. A total of 16 of 23 patients (69.6%) were found to have VB6 deficiency, but VB6 supplementation with pyridoxal phosphate hydrate did not elevate hemoglobin levels in deficient patients. None of the patients presented with vitamin B12, iron, or copper deficiencies. Four patients showed serum folate levels below the lower limit of normal and eight patients showed serum zinc levels below the lower limit of normal; however, these deficiencies were marginal and unlikely to contribute to anemia. Compared to VB6-sufficient patients, VB6-deficient patients showed significantly lower serum folate levels and higher serum copper levels. Studies elucidating the relationship of VB6 deficiency and etiology of PMF/sMF are warranted.

To access the full text, please Sign in

If you have institutional access, please click here

Share the Knowledge